Arovella Therapeutics Limited (ASX:ALA)
Australia · Delayed Price · Currency is AUD 0.0650
+0.0010 (1.56%)
Aug 21, 2026, 3:57 PM AEST
Arovella Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | - | 0.14 | 0.02 | 0.41 | 0.3 |
Other Revenue | 4.3 | 3.3 | 1.94 | 1.05 | - |
| 4.3 | 3.44 | 1.95 | 1.45 | 0.3 | |
Revenue Growth | 24.94% | 76.22% | 34.20% | 391.75% | -70.11% |
Cost of Revenue | - | - | - | 0.2 | 0.21 |
Gross Profit | 4.3 | 3.44 | 1.95 | 1.25 | 0.09 |
Selling, General & Admin | 2.79 | 2.21 | 1.36 | 1.5 | 1.32 |
Research & Development | 5.87 | 6.52 | 6.74 | 3.98 | 2.6 |
Other Operating Expenses | 1.96 | 1.65 | 1.64 | 2.7 | 2.63 |
Operating Expenses | 11.21 | 11.34 | 10.83 | 9.88 | 7.69 |
Operating Income | -6.92 | -7.9 | -8.88 | -8.63 | -7.6 |
Interest Expense | - | - | -0.01 | -0 | -0.19 |
Interest & Investment Income | - | 0.39 | 0.14 | 0.03 | 0 |
Other Non Operating Income (Expenses) | - | - | - | -0.02 | -0 |
EBT Excluding Unusual Items | -6.92 | -7.51 | -8.75 | -8.62 | -7.79 |
Asset Writedown | - | - | - | -1.56 | -0.83 |
Pretax Income | -6.92 | -7.51 | -8.75 | -10.18 | -8.62 |
Earnings From Continuing Operations | -6.92 | -7.51 | -8.75 | -10.18 | -8.62 |
Net Income | -6.92 | -7.51 | -8.75 | -10.18 | -8.62 |
Net Income to Common | -6.92 | -7.51 | -8.75 | -10.18 | -8.62 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 1,192 | 1,097 | 941 | 711 | 550 |
Shares Outstanding (Diluted) | 1,192 | 1,097 | 941 | 711 | 550 |
Shares Change | 8.69% | 16.55% | 32.32% | 29.45% | 66.10% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -6.95 | -7.34 | -7.04 | -6.4 | -6.3 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Gross Margin | 100.00% | 100.00% | 100.00% | 86.01% | 30.00% |
Operating Margin | -160.92% | -229.61% | -454.69% | -593.40% | -2568.01% |
Profit Margin | -160.92% | -218.28% | -448.03% | -699.91% | -2914.23% |
Free Cash Flow Margin | -161.59% | -213.45% | -360.80% | -439.99% | -2130.85% |
EBITDA | -6.8 | -7.79 | -8.83 | -8.53 | -7.46 |
EBITDA Margin | -158.18% | -226.49% | - | - | - |
D&A For EBITDA | 0.12 | 0.11 | 0.04 | 0.1 | 0.14 |
EBIT | -6.92 | -7.9 | -8.88 | -8.63 | -7.6 |
EBIT Margin | -160.92% | -229.61% | - | - | - |